Neurovascular Devices – Market Insights – Asia Pacific

The Asia Pacific neurovascular device market will grow moderately through the forecast period, driven by rising procedure volumes, anticipated product launches, and increasing affordability of neurovascular procedures supported by key government initiatives and positive clinical data. In the current report iteration, coverage has been expanded to include angioplasty devices, resulting in a higher overall number of neurovascular procedures captured in the market analysis. At the same time, the market continues to experience ASP declines and intensified price competition, primarily driven by the impact of VBP in China.

This Medtech 360 Report provides comprehensive data and analysis on the state of the market for neurovascular devices in Asia Pacific from 2019 through 2035.

China’s centralized procurement measures will impact the overall neurovascular device market.

What are the major changes in the ASPs of various neurovascular devices after the implementation of VBP?

How has the market shifted dynamically following VBP implementation?

Which companies have gained market shares, and which have been negatively impacted?

Emergence of evidence supporting use of embolization devices in the treatment of chronic subdural hematoma will support growth of neurovascular embolization procedure volumes.

Which embolization devices will see the strongest adoption in the treatment of chronic subdural hematoma?

How will the uptake of embolization procedures in the treatment of chronic subdural hematoma vary across the Asia Pacific region?

Which companies will see market share gains?

The rising stroke population in India and China is leading to an increase in the cases associated with ICAD, fueling the adoption of intracranial angioplasty devices and supporting growth of interventional procedure volumes.

Which angioplasty devices will see the strongest adoption in the treatment of ICAD?

Which countries in the Asia Pacific region presently have the highest patient population affected by ICAD with sever stenosis?

Which are the leading players in the Asia Pacific neurovascular device market?

The underpenetrated Indian and Chinese neurovascular device markets have strong growth potential.

Which factors are responsible for low penetration of neurovascular devices in India and China?

What impact have clinical guidelines and new government initiatives had on various device segments in these countries?

What strategies are competitors using in these markets to gain revenues?

Neurovascular thrombectomy devices and neurovascular embolization devices are fueling growth of overall neurovascular device market.

What factors are driving the adoption of neurovascular thrombectomy in Australia and India?

What is the growth outlook of these market segments in the Asia Pacific region?

How the impact of VBP on liquid embolics—embolic glue—and embolization particles—microspheres and PVA particles—will shape the market dynamics in China?

How will the uptake of these devices vary across the countries covered?

Clinical data will play an important role in driving the adoption of neurovascular devices.

Which clinical trials were recently conducted in this market?

What is the expected impact of these clinical trials on market dynamics?